Clinical trials: Thoracic Tumor
Non Small Cell Lung Cancer
Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
This study evaluates Navtemadlin (KRT-232) in combination with Pembrolizumab as a maintenance therapy in patients with locally advanced and metastatic non small cell lung cancer.
- Trial name
- NCT05705466
- Testing
- Navtemadlin, Pembrolizumab
- Sponsor
- Kartos Therapeutics, Inc.
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer
- Trial name
- MDX1106-01 (NCT00441337)
- Testing
- MDX-1106
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Cancer, Breast Cancer
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
This is a Phase 1, first-in-human, dose escalation study in participants with advanced solid tumors to determine the pharmacokinetics, maximum tolerated dose and the recommended Phase 2 dose of ABBV-075 at different monotherapy…
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Acute Myeloid Leukemia (AML)
- Trial name
- NCT02391480
- Testing
- ABBV-075, Venetoclax
- Where
- 10 sites in United States
- Volunteers
- 128 people
- Sponsor
- AbbVie
Carcinoma, Non-Small-Cell Lung
A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
The primary purpose of this study is to compare the efficacy of the study drug LY2875358, given together with erlotinib, against erlotinib, alone.
- Trial name
- Balise (NCT01897480)
- Testing
- LY2875358, Erlotinib
- Where
- 45 sites in Denmark, France and 7 more
- Volunteers
- 168 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Cancer, Neuroendocrine Carcinoma
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.
- Trial name
- NCT07038096
- Testing
- ZG006, ZG005
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Solid Tumor, TNBC - Triple-Negative Breast Cancer
TH1902 in Patients With Advanced Solid Tumors
Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard…
- Conditions
- Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT04706962
- Testing
- TH1902
- Where
- 6 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Theratechnologies
Small-cell Lung Cancer, Neuroendocrine Carcinomas
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
- Conditions
- Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
- Trial name
- NCT07174583
- Testing
- IDE849, durvalumab, IDE161
- Where
- 13 sites in United States
- Volunteers
- 262 people
- Sponsor
- IDEAYA Biosciences
Carcinoma, Small Cell Lung
RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer
This Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.
- Trial name
- REPLATINUM (NCT03699956)
- Testing
- RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide
- Where
- 18 sites in United States
- Volunteers
- 18 people
- Sponsor
- EpicentRx, Inc.
Lung Cancer, Pulmonary Nodule, Solitary
Prospective Post-market Data Collection for Ion Endoluminal System to Understand CT to Body Divergence
The goal of this study is to collect post-market data for the Ion Endoluminal System to understand CT to body divergence.
- Trial name
- NCT04735341
- Testing
- Ion Endoluminal System
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Intuitive Surgical
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant
Non-small Cell Lung Cancer Registry
This trial will evaluate two separate groups of patients with stage IIIB/IV non-small cell lung cancer. The objective of Group 1 is to investigate an FDA-approved drug in stage IIIB/IV non-small cell lung cancer patients that has…
- Trial name
- NCT00099541
- Testing
- zoledronic acid
- Where
- 101 sites in United States
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)
The primary objective of this study is to assess the safety and pharmacokinetics of linifanib, and identify tolerable dose of linifanib (ABT-869) in combination with carboplatin and paclitaxel in Japanese subjects with advanced…
- Trial name
- NCT01225302
- Testing
- Linifanib, Carboplatin, Paclitaxel
- Volunteers
- 12 people
- Sponsor
- AbbVie
Neoplasms, Carcinoma, Non-Small-Cell Lung
Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC
Primary objective of this study is to allow access and evaluate the safety of crizotinib for patients in Japan with advanced NSCLC harboring a translocation or inversion involving the ROS1 oncogene.
- Trial name
- NCT02824094
- Testing
- crizotinib
- Where
- 4 sites in Japan
- Sponsor
- Pfizer
Lung Cancer, Non-Small Cell
Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer
The primary purpose of this study is to evaluate the safety and tolerability of the combination therapy of trametinib and docetaxel with growth factor support in Japanese subjects with Stage IV or a postoperative recurrence…
- Trial name
- NCT01938456
- Testing
- Trametinib, Docetaxel, Filgrastim
- Sponsor
- GlaxoSmithKline
Lung Cancer
NovellusDx Functional Profiling of Oncogenic Mutations in Lung Cancer Patients
NovellusDx technology identifies tumor-specific driver mutations, but unlike sequencing-based tests, NovellusDx has a functional assay that detects dis-regulated translocation of mutated signaling proteins to the nucleus.
- Trial name
- NCT02274025
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Fore Biotherapeutics
Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC)
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
This is a multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of B1962 in the treatment of ad-vanced solid tumors.
- Conditions
- Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer
- Trial name
- NCT06724263
- Testing
- B1962
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Advanced Cancer, Ovarian Cancer
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.
- Conditions
- Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT03667716
- Testing
- COM701, COM701 with Opdivo (Nivolumab).
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- Compugen Ltd
Mesothelioma, Mesotheliomas Pleural
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit…
- Conditions
- Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum
- Trial name
- NCT05451849
- Testing
- TC-510, Fludarabine, Cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- TCR2 Therapeutics
Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
The study will first determine the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving first line anti-PD(L)1 treatment for locally advanced or…
- Trial name
- NCT05403385
- Testing
- inupadenant, Carboplatin, Pemetrexed
- Where
- 21 sites in United States, Belgium and 6 more
- Volunteers
- 36 people
- Sponsor
- iTeos Therapeutics
Colorectal Cancer, Esophageal Cancer
Clinical Trial Protocol for Evaluating the Efficacy and Safety of Thoracoabdominal Endoscopic Surgery System in Remote Laparoscopic Surgery for Urology, General Surgery, Gynecology and Thoracic Surgery
Evaluation of the Efficacy and Safety of the Thoracoabdominal Endoscopic Surgery System Produced by Shenzhen Cornerstone Robotics Technology Co., Ltd.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Hepatectomy, Radical Hysterectomy
- Trial name
- NCT07382635
- Testing
- Robot-assisted surgery
- Volunteers
- 98 people
- Sponsor
- Cornerstone Robotics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.